Clinical trials: Immune Checkpoint Inhibitor-Related Colitis, open to volunteers
Immune-related Colitis, Colitis
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
Immune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL).
- Trial name
- NCT05726396
- Testing
- RMT
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Minnesota
Immune Checkpoint Inhibitor-Related Colitis
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint inhibitor colitis (ICI…
- Trial name
- EVITA (NCT06841705)
- Testing
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Shilpa Grover, MD, MPH
Cancer
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients.
- Trial name
- NCT06807593
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
IrAE, Immune-related Adverse Event
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard…
- Conditions
- IrAE, Immune-related Adverse Event, Diarrhea, Colitis
- Trial name
- NCT06337695
- Testing
- Vedolizumab
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- AHS Cancer Control Alberta
Colitis, Hepatitis
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
- Conditions
- Colitis, Hepatitis, Melanoma (Skin Cancer)
- Trial name
- PHOENIX-ECP (NCT07619898)
- Testing
- methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab
- Volunteers
- 112 people
- Sponsor
- Therakos LLC